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Objective: In the present study, a novel series of 1, 3, 4-thiadiazole derivatives were docked against the mycobacterium tuberculosis protein kinase 
G. 1, 3, 4–thiadiazole derivatives with a modified primary amine group at 5th
Methods: The three-dimensional structure of the protein was obtained from PDB, and its active sites were predicted. The structures of all the 
compounds were drawn using chemdraw software version 8.0. The docking studies were done by using schrödinger software against the enzyme 
protein kinase G. Totally eighteen compounds was synthesized based on glide score 
 position were used for docking studies.  
Results: In this Docking study the thiadiazole analogues were showing good binding energy. The amino acids residues GLU588, SER412, GLY410 and 
GLU 628 in the kinase domain active site form hydrogen bonds with the ligand.  
Conclusion: The compounds D34, D16, D7, D25, D15, and D27 showed better interaction with protein kinase G (pknG) more than the other drug molecules 
Keywords: Thiadiazole derivatives, molecular docking, Schroodinger software, ligand binding energy, protein kinase G enzyme, mycobacterium 
tuberculosis 




Mycobacterium tuberculosis (MTB) is an aerobic pathogenic bacteria 
and is the causative agent of most cases of tuberculosis. 
Tuberculosis (TB) is a lung infection and is highly contagious and 
deadly disease. The reason for the widespread of this disease is the 
emergence of multi-drug resistant TB strains and less availability of 
a new drug with a novel mechanism of action [1]. 
A permanent solution to this disease will be the development of 
vaccines. But the most reliable will be chemotherapy, which requires 
effective and non-toxic antitubercular agents. The identification of 
new target sites will decrease the problems associated with multi-
drug resistant strains, for this biochemical pathway specific to the 
mycobacterium disease cycle must be better understood [2]. 
This strategy and the conditions have indulged in the development 
of new thiadiazole moieties as antitubercular drugs by inhibiting the 
important enzymes involved in the bacterial life cycle. The enzyme 
protein kinase G (PKnG) is not needed for mycobacteria growth, but 
this enzyme is very much important for the survival of 
Mycobacterium in the host macrophages [3] and has marked as the 
best target enzyme protein for docking studies. Different 1 3 4 
thiadiazole derivatives are considered as ligands or drug molecules 
which are going to interact with the enzyme thus inhibiting its 
activity [4]. 
Pathogenecity of mycobacteria is due to its survival in host cell 
macrophages. All phagocytosized microbes are rapidly transferred 
from host cell macrophages to lysosomes and degraded. 
Mycobacteria resist lysosomal delivery and also reuptake into 
macrophages, so they survive intracellularly. This is due to protein 
kinase G secreted from mycobacteria which inhibit macrophages 
lysosome fusion causing the survival of the bacteria. Chemical 
inhibition of protein kinase G causes lysosomal localization and 
mycobacterial cell death [5]. This enzyme inhibition is done by drug 
molecules or ligands binding with the enzymes. The binding capacity 
of the ligand with the enzyme was analysed by docking studies. The 
present study was carried out to evaluate the efficiency of the 
thiadiazole compounds against mycobacteria using molecular 
docking studies with the objective to find potential drug targets.  
MATERIALS AND METHODS  
Schrodinger software version was used for the docking studies. For 
the determination of protein–Ligand binding affinities and scoring 
function GLIDE 4.0 (Grid Based Ligand Docking with Energies) XP 
(Extra Precision) docking protocol was used. 
Ligand preparation 
The 3D structure of the ligand 1, 3, 4-thiadiazoles with calculated 
molecular weight from 240 and its derivatives (table 2) were drawn 
using chemdraw software version 8.0. The basic structure of thiadiazole 
was got from pubmed database. The ligand structures were constructed 
using the splinter dictionary of Maestro 9.4 (Schrodinger, LLC) using the 
Optimized Potentials for Liquid Simulations-All Atom (OPLS-AA) force 
field [7] with the steepest descent followed by curtailed Newton 
conjugate gradient protocol. Partial atomic charges were computed 
using the OPLS-AA force field [6]. 
Protein/enzyme preparation 
The X-ray crystal structures protein kinase G (PDB: 2PZI) retrieved 
from the Research Collaboratory for Structural Bioinformatics 
(RCSB) Protein Data Bank was used in the present study. Water 
molecules of crystallization were detached from the composite, and 
the protein was optimized for docking using the protein preparation 
and refinement utility provided by Schrödinger LLC. Partial atomic 
charges were assigned according to the OPLS-AA force field.  
Bind site analysis 
Active sites or binding sites for enzymes were predicted from a 
pictorial database of 3D structures in the protein data bank (PDB sum), and 
Q-Site Finder software from university of Leeds Bioinformatics was used 
for ligand binding site prediction. In that 6 sites where found active (1 
for ligands and 5 for metals). So it was decided to keep all the amino 
acids in the active site of the enzyme [7]. 
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RESULTS AND DISCUSSION 
In this work, totally 40 compounds of thiadiazoles derivatives with 
modifications in the amino group of 5th position were used for the 
study. Six targets of binding sites on the crystallographic structure 
of the enzyme have been examined for ligand-based docking 
program. The ligands are screened for their ability to dock within 
the active site of the enzyme. Virtual screening is not performed to 
find the numbers of a chemical compound which inhibit the activity 
of the enzyme. Instead extra precision mode (XP) were used. More 
negative glide score value indicates a good interaction of the ligand 
with the target protein. After analyzing the different docking 
interactions of ligands, the compounds namely D34, D16, D7, D25, 
D15, and D27 showed fairly better interaction with protein kinase 
(PknG) with the more negative G-Score value than the other drug 
molecules. The amino acids residues GLU588, SER412, GLY410 and 
GLU 628 in the kinase domain (fig. 1, 2 and 3) form hydrogen bonds 
with the ligands. The amino acids like serine and glutamine form 
hydrogen bonds with the drug molecules of D series. 
Compound D34 which is a chalcone derivative of thiadiazole 
contains pyridyl group at 2nd position (R Group) and a m-Hydroxy–
p-Methoxy Phenyl group at substituted at the amino group of 5th 
position (R1 position) possess high glide score value-6.69 and glide 
energy value of-42.64 which shows best ligand and enzyme 
interaction. Also, compound D16 which contains a p-hydroxyphenyl 
group at R position and a dimethyl aminophenyl group at position 
R1 showed high glide score with-6.62 and glide energy of-48.62. 
Many compounds in D series showed good interaction with the 
enzyme, having glide score range from-4.8 to-6.69 (table 1). 
Mycobacterium tuberculosis PknG is an essential receptor-like protein 
kinase involved in cell growth control. M. tuberculosis PKnG is a trans-
membrane Ser/Thr protein kinase (STPK) highly conserved in gram-
positive bacteria and apparently essential for viability [8]. 
The thiadiazole derivatives and its different analogues were found to 
bind with protein kinase enzyme. The docking screening was performed 
by employing the scoring function. The result was based on the score of 
estimated free energy, inhibition constant, and hydrogen bonding. 
  
Table 1: Data of estimated docking parameters of thiadiazole analogues with protein kinase G 
Title Docking score XP G score Glide G score Glide energy Glide E internal xp h bond Glide ligand efficiency [8] 
2PZI        
D34. mol -6.3394 -6.6935 -6.6935 -42.6465 0 -2.01368 -0.26774 
D16. mol -6.2503 -6.6269 -6.6269 -48.6215 15.19324 -0.35539 -0.24544 
D7. mol -5.8741 -6.2339 -6.2339 -43.7537 4.487678 -0.9 -0.25975 
D25. mol -5.8323 -6.1465 -6.1465 -47.7566 8.266831 -1.18 -0.23641 
D15. mol -5.7560 -6.1027 -6.1027 -42.2412 9.169291 -2.85873 -0.25428 
D27. mol -5.673 -6.246 -6.2463 -43.7829 10.34215 -0.9975 -0.26026 
D33. mol -5.4844 -5.9822 -5.9822 -41.3284 11.96712 -1.95 -0.2601 
D17. mol -5.3738 -5.7475 -5.7475 -41.0715 7.604469 -0.7 -0.2299 
D14. mol -5.0956 -5.4423 -5.4423 -47.0438 0 -1.51683 -0.20932 
D26. mol -5.0464 -5.3673 -5.3673 -47.2284 13.75001 -0.7 -0.20644 
D10. mol -4.9576 -5.2905 -5.2905 -40.19 7.479155 -0.29881 -0.23002 
D39. mol -4.8320 -5.1939 -5.1939 -41.3978 12.04666 0 -0.22583 
D36. mol -4.7932 -5.2721 -5.2721 -41.488 3.481447 -0.23762 -0.22923 
D9. mol -4.6992 -5.0539 -5.0539 -41.6236 0 -0.68761 -0.21974 
D30. mol -4.6905 -5.0047 -5.0047 -41.2029 5.028046 -0.05378 -0.20853 
D24. mol -4.5593 -5.1842 -5.1842 -43.8498 17.06249 -0.7 -0.23565 
D28. mol -4.5470 -4.8612 -4.8612 -42.9364 9.682065 0 -0.20255 
D8. mol -4.5356 -4.8685 -4.8685 -41.0375 9.210653 -0.49952 -0.21168 
D29. mol -4.4410 -5.0136 -5.0136 -42.2539 6.16229 -1.37057 -0.2089 
D21. mol -4.3420 -4.6562 -4.6562 -40.4049 7.941264 -1.03888 -0.20245 
D2. mol -4.3106 -4.6435 -4.6435 -43.1724 8.176312 0 -0.19348 
D22. mol -4.2770 -4.5912 -4.591 -41.656 11.264 -0.6537 -0.1836 
D5. mol -4.2158 -4.4479 -4.4479 -40.1022 4.208613 -0.7 -0.21181 
D32. mol -4.1778 -4.5397 -4.5397 -43.5986 8.83195 -0.07374 -0.18916 
D12. mol -4.1573 -4.466 -4.46 -44.3128 7.143773 -0.56692 -0.17864 
D40. mol -4.1241 -4.8366 -4.83667 -36.6305 9.555526 -0.45638 -0.23032 
D38. mol -4.1169 -4.5018 -4.50183 -43.3633 8.564388 -0.2938 -0.19573 
D13. mol -4.0203 -4.6467 -4.64677 -41.3201 11.99485 -0.89203 -0.21122 
D1. mol -3.9445 -4.2774 -4.27743 -33.6689 13.21224 -0.084 -0.19443 
D31. mol -3.9302 -4.3940 -4.39404 -27.7501 13.77523 -0.39136 -0.19973 
D6. mol -3.9295 -4.2924 -4.29247 -42.914 11.81976 0 -0.1651 
D3. mol -3.9106 -4.2142 -4.21422 -41.3832 4.710607 -0.65721 -0.18323 
D35. mol -3.8009 -4.1932 -4.19328 -45.9145 6.055371 -0.7 -0.16773 
D23. mol -3.7838 -4.0980 -4.09804 -39.1289 6.106972 -1.31092 -0.17075 
D4. mol -3.7459 -4.2672 -4.26725 -46.0125 11.90417 -1.99717 -0.17069 
D18. mol -3.6395 -3.9862 -3.98628 -46.2679 3.122691 -1.04324 -0.1661 
D11. mol -3.5951 -4.1160 -4.11603 -48.3259 9.010351 -0.35 -0.15245 
D19. mol -3.2861 -3.6328 -3.63287 -36.1451 0.670452 -0.32319 -0.15137 
D37. mol -3.1718 -3.5337 -3.53376 -41.5995 7.738014 -1.4114 -0.15364 
D20. mol -2.1184 -2.4651 -2.46517 -43.0892 10.58537 0 -0.10272 
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Table 2: 1 3 4 thiadiazole derivatives of D-series 
Compound code R R1 
D1–D10 C6H5-phenyl  D1 Phenyl 
D2 4-methoxy phenyl 
D3 2-hydroxy phenyl 
D4 3-hydroxy-4-methoxy phenyl 
D5 Furfuryl 
D6 p-dimethyl amino phenyl 
D7 2-amino phenyl 
D8 3-amino phenyl 
D9 4-amino phenyl 
D10 4-hydroxy phenyl 
D11–D20 4–Hydroxyl phenyl D11 Phenyl 
D12 4-methoxy phenyl 
D13 2-hydroxy phenyl 
D14 3-hydroxy-4-methoxy phenyl 
D15 Furfuryl 
D16 p-dimethyl amino phenyl 
D17 2-amino phenyl 
D18 3-amino phenyl 
D19 4-amino phenyl 
D20 4-hydroxy phenyl 
D21–D30 2-Hydroxy Phenyl D21 Phenyl 
D22 4-methoxy phenyl 
D23 2-hydroxy phenyl 
D24 3-hydroxy-4-methoxy phenyl 
D25 Furfuryl 
D26 p-dimethyl amino phenyl 
D27 2-amino phenyl 
D28 3-amino phenyl 
D29 4-amino phenyl 
D30 4-hydroxy phenyl 
 
D31–D40 
Pyridyl D31 Phenyl 
D32 4-methoxy phenyl 
D33 2-hydroxy phenyl 
D34 3-hydroxy-4-methoxy phenyl 
D35 Furfuryl 
D36 p-dimethyl amino phenyl 
D37 2-amino phenyl 
D38 3-amino phenyl 
D39 4-amino phenyl 
D40 4-hydroxy phenyl 
 
 
Fig. 1: Interaction of the compound D7 with the enzyme 
Geetha et al. 




Fig. 2: Interaction of compound D16 with the enzyme 
 
 
Fig. 3: Interaction of compound D34 with the enzyme 
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On comparing the glide score values, the better interaction was 
shown by compounds D34, D16, D7, and D25 with glide score values-
6.69,-6.62,-6.23 and-6.14 respectively. Thus by analyzing these datas 
1 3 4 thiadiazole derivatives can be considered as a potent inhibitor 
against the enzyme protein kinase in Mycobacterium tuberculosis. 
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